Evercore ISI cuts Ultragenyx Pharma PT to $16.00 from $34.00
Evercore ISI Group cut its price target for Ultragenyx Pharma to $16.00 per share from $34.00 and moved the rating to In-Line from Outperform, per Benzinga.
Ultragenyx Pharma was cut to In-Line from Outperform by Evercore ISI Group, according to Benzinga.